Treating melanoma in adolescents and young adults: challenges and solutions

References

• Coccia PF, Pappo AS, Altman J, et al. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014;12(1):21–32; quiz 32.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Ulrich C, Martin S. Young adults, cancer, health insurance, socioeconomic status, and the Patient Protection and Affordable Care Act. Cancer. 2012;118(24):6018–6021.
   Web of Science ®Google Scholar
• Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma – lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103(9):1891–1897.
   Web of Science ®Google Scholar
• Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107(7 Suppl):1645–1655.
   Web of Science ®Google Scholar
• Reed D, Block RG, Johnson R. Creating an adolescent and young adult cancer program: lessons learned from pediatric and adult oncology practice bases. J Natl Compr Canc Netw. 2014;12(10):1409–1415.
   Web of Science ®Google Scholar
• Rizzari C, Putti MC, Colombini A, et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep. 2014;6(3):5554.
   Google Scholar
• Bleyer A. The Quid Pro Quo of pediatric versus adult services for older adolescent cancer patients. Pediatr Blood Cancer. 2010;54(2):238–241.
   Web of Science ®Google Scholar
• ICH. Guidance for Industry E11 Clinical Investigation of Medicinal Products in the Pediatric Population. 2000. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073143.pdf. Accessed May 29, 2015.
   Google Scholar
• Field MJ, Behrman RE, Committee on Clinical Research Involving Children. The necessity and challenges of clinical research involving children. In: Institute of Medicine (US) Committee on Clinical Research Involving Children, Field MJ, Behrman RE, editors. Ethical Conduct of Clinical Research Involving Children. Washington, DC, USA: National Academies Press; 2004:64–66.
   Google Scholar
• Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013;167(10):926–932.
   PubMed Web of Science ®Google Scholar
• Robbins AS, Lerro CC, Barr RD. Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010. Cancer. 2014;120(8):1212–1219.
   Web of Science ®Google Scholar
• American Cancer Society. Melanoma Skin Cancer. 2015. Available from: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics. Accessed June 4, 2015.
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Program: SEER Stat Fact Sheets: Melanoma of the Skin [webpage on the Internet]. 2015. Available from: http://seer.cancer.gov/statfacts/html/melan.html. Accessed June 1, 2015.
   Google Scholar
• Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, Cormier JN. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 2013;48(11):2207–2213.
   PubMed Web of Science ®Google Scholar
• Helvind NM, Holmich LR, Smith S, et al. Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a National Database Study of 24 059 melanoma cases. JAMA Dermatol. Epub 2015 Jun 10.
   Google Scholar
• AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012: cancer in children and adolescents. Epidemiol Prev. 2013;37(1 Suppl 1):1–225.
   Google Scholar
• Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953–2008 – are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400.
   PubMed Web of Science ®Google Scholar
• Rajput A, Faizi SA, Nir I, et al. Pediatric melanoma in New Mexico American Indians, Hispanics, and non-Hispanic whites, 1981–2009. Am J Surg. 2014;207(3):412–416; discussion 416.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115(3):649–654.
   Web of Science ®Google Scholar
• Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39(18):2651–2661.
   Web of Science ®Google Scholar
• Lange JR PB, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Database. J Clin Oncol. 2007;25(11):1363–1368.
   Web of Science ®Google Scholar
• Cordoro KM, Gupta D, Frieden IJ, McCalmont T, Kashani-Sabet M. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013;68(6):913–925.
   PubMed Web of Science ®Google Scholar
• Cerrato F, Wallins JS, Webb ML, McCarty ER, Schmidt BA, Labow BI. Outcomes in pediatric atypical spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol. 2012;29(4):448–453.
   PubMed Web of Science ®Google Scholar
• DeDavid M, Orlow SJ, Provost N, et al. A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol. 1997;36(3 Pt 1):409–416.
   Web of Science ®Google Scholar
• Gerami P, Cooper C, Bajaj S, et al. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37(9):1387–1394.
   Web of Science ®Google Scholar
• McCormack CJ, Conyers RK, Scolyer RA, et al. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014;24(5):437–447.
   Web of Science ®Google Scholar
• Moscarella E, Zalaudek I, Cerroni L, et al. Excised melanocytic lesions in children and adolescents – a 10-year survey. Br J Dermatol. 2012;167(2):368–373.
   PubMed Web of Science ®Google Scholar
• Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod Pathol. 2006;19(Suppl 2):S21–S33.
   PubMedGoogle Scholar
• Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol. 1999;135(3):282–285.
   Google Scholar
• Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005;52(2):197–203.
   PubMed Web of Science ®Google Scholar
• Zaal LH, Mooi WJ, Klip H, van der Horst CM. Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg. 2005; 116(7):1902–1909.
   Web of Science ®Google Scholar
• Gerami P, Busam K, Cochran A, et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol. 2014;38(7):934–940.
   PubMed Web of Science ®Google Scholar
• Gerami P, Wass A, Mafee M, Fang Y, Pulitzer MP, Busam KJ. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol. 2009;33(12):1783–1788.
   Web of Science ®Google Scholar
• Piepkorn MW, Barnhill RL, Elder DE, et al. The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. J Am Acad Dermatol. 2014;70(1):131–141.
   PubMed Web of Science ®Google Scholar
• Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw. 2013;11(6):679–686.
   PubMed Web of Science ®Google Scholar
• Mills OL, Marzban S, Zager JS, Sondak VK, Messina JL. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol. 2012;39(3):331–336.
   PubMed Web of Science ®Google Scholar
• Sreeraman Kumar RM JL, Reed D, Navid F, Sondak VK. Pediatric melanoma and atypical melanocytic neoplasms. In: Kaufman HL, editor. Cancer Treatment and Research: Melanoma. New York (NY): Springer; 2015.
   Google Scholar
• Sondak VK, Reed DR, Messina JL. A comprehensive approach to pediatric atypical melanocytic neoplasms, with comment on the role of sentinel lymph node biopsy. Crit Rev Oncog. In press 2015.
   Google Scholar
• Miglioretti DL, Johnson E, Williams A, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013;167(8):700–707.
   PubMed Web of Science ®Google Scholar
• Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499–505.
   PubMed Web of Science ®Google Scholar
• Wong JY, Sondak VK. Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Netw. 2012;10(3):357–365.
   Web of Science ®Google Scholar
• Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247–258.
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.
   PubMed Web of Science ®Google Scholar
• Han D, Zager JS, Han G, et al. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012;19(12):3888–3895.
   Web of Science ®Google Scholar
• Han D, Turner LM, Reed D, Messina JL, Sondak VK. The prognostic significance of lymph node metastasis in pediatric melanoma and atypical melanocytic proliferations. Expert Rev Dermatol. 2013;8(2):103–106.
   Google Scholar
• Averbook BJ, Lee SJ, Delman KA, et al. Pediatric melanoma: analysis of an international registry. Cancer. 2013;119(22):4012–4019.
   PubMed Web of Science ®Google Scholar
• Palmer PE 3rd, Warneke CL, Hayes-Jordan AA, et al. Complications in the surgical treatment of pediatric melanoma. J Pediatr Surg. 2013;48(6):1249–1253.
   Web of Science ®Google Scholar
• Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387–4393.
   PubMed Web of Science ®Google Scholar
• Howman-Giles R, Shaw HM, Scolyer RA, et al. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol. 2010;17(1):138–143.
   Web of Science ®Google Scholar
• Urso C, Borgognoni L, Doria M, Tinacci G, Zini E. Non-sentinel lymph node involvement in a patient with an atypical Spitz tumor and a positive sentinel node. Report of a case and review of the literature. J Cutan Pathol. 2009;36(5):586–590.
   Web of Science ®Google Scholar
• Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15(4):1202–1210.
   Web of Science ®Google Scholar
• McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9(2):137–141.
   PubMed Web of Science ®Google Scholar
• Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28(29):4441–4449.
   PubMed Web of Science ®Google Scholar
• Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012; 30(23):2912–2918.
   PubMed Web of Science ®Google Scholar
• Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005;40(1):232–235.
   Web of Science ®Google Scholar
• van der Ploeg IM, Valdes Olmos RA, Kroon BB, Nieweg OE. Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: superficial or superficial and deep lymph node dissection? Ann Surg Oncol. 2008;15(5):1485–1491.
   Web of Science ®Google Scholar
• Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17(12):3324–3329.
   PubMed Web of Science ®Google Scholar
• Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009;16(3):240–247.
   Web of Science ®Google Scholar
• Sondak VK, Gibney GT. Indications and options for systemic therapy in melanoma. Surg Clin North Am. 2014;94(5):1049–1058.
   Web of Science ®Google Scholar
• Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis and treatment, as reported in the journal Cancer. Cancer. 2008;1;113(7 Suppl):1728–1743.
   Google Scholar
• Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–784.
   PubMed Web of Science ®Google Scholar
• Lu C, Zhang J, Nagahawatte P, et al. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135(3):816–823.
   Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707–714.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol. 2013;31(4):499–506.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–1196.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolimab in previously untreated melanoma without BRAF mutation. New Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006–2017.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530.
   PubMed Web of Science ®Google Scholar
• Shah NC, Gerstle JT, Stuart M, Winter C, Pappo A. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28(8):496–500.
   Web of Science ®Google Scholar
• Chao MM, Schwartz JL, Wechsler DS, Thornburg CD, Griffith KA, Williams JA. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2005;44(5):441–448.
   Web of Science ®Google Scholar
• Navid F, Furman WL, Fleming M, et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer. 2005;103(4):780–787.
   Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
   PubMed Web of Science ®Google Scholar
• Mathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007;60(3):471–481; discussion 481–472.
   PubMed Web of Science ®Google Scholar
• Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg. 2005;83(5–6):213–221.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–870.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
   PubMed Web of Science ®Google Scholar
• Park SS, Dong H, Zhao W, et al. PD-1 blockade enhances radiation therapy-induced abscopal effect. Int J Radiat Oncol Biol Phys. 2014; 90(1):S57–S58.
   Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377.
   PubMed Web of Science ®Google Scholar
• Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503–510.
   PubMed Web of Science ®Google Scholar
• Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994;30(4):795–798.
   PubMed Web of Science ®Google Scholar
• Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116(2):169–172.
   PubMedGoogle Scholar
• Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836–5844.
   Web of Science ®Google Scholar
• Guadagnolo BA, Zagars GK. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol. 2009;10(4):409–416.
   Web of Science ®Google Scholar
• Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4):1051–1055.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589–597.
   PubMed Web of Science ®Google Scholar
• Pinkham MB, Foote MC, Burmeister E, et al. Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(4):702–708.
   Web of Science ®Google Scholar
• Mendenhall WM, Shaw C, Amdur RJ, Kirwan J, Morris CG, Werning JW. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence. Am J Otolaryngol. 2013;34(4):320–322.
   Web of Science ®Google Scholar
• Ahmed S, Kottschade L, Markovic S, Garces Y, Foote R. Adjuvant radiotherapy for melanoma metastatic to axillary and inguinal nodes: regional tumor control and late effects. J Cancer Res Ther. 2014;2(9):144–152.
   Google Scholar
• Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015;13(4):277–289; quiz 290.
   PubMed Web of Science ®Google Scholar
• Murphy D, Orgel E, Termuhlen A, Shannon S, Warren K, Quinn GP. Why healthcare providers should focus on the fertility of AYA cancer survivors: it’s not too late! Front Oncol. 2013;3:248.
   Google Scholar
• Coit DG, Thompson JA, Andtbacka R, et al. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014;12(5):621–629.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Cecchetto G, et al. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr. 2014;164(2):376–382. e371–e372.
   Web of Science ®Google Scholar
• Parsons HM, Schmidt S, Harlan LC, et al. Young and uninsured: Insurance patterns of recently diagnosed adolescent and young adult cancer survivors in the AYA HOPE study. Cancer. 2014;120(15):2352–2360.
   Web of Science ®Google Scholar
• Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011;29(30):4045–4053.
   Web of Science ®Google Scholar
• Zebrack B, Kent EE, Keegan TH, Kato I, Smith AW, Group AHSC. “Cancer sucks,” and other ponderings by adolescent and young adult cancer survivors. J Psychosoc Oncol. 2014;32(1):1–15.
   PubMed Web of Science ®Google Scholar
• Barakat LP, Schwartz LA, Reilly A, Deatrick JA, Balis F. A qualitative study of phase III cancer clinical trial enrollment decision-making: perspectives from adolescents, young adults, caregivers, and providers. J Adolesc Young Adult Oncol. 2014;3(1):3–11.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; World Health Organization. Available from: http://globocan.iarc.fr/Pages/age-specific_table_sel.aspx. Accessed August 21, 2015.
   Google Scholar